GHRH Therapy Explored for Improving Heart Function in Congestive Heart Failure
Background
Congestive Heart Failure (CHF) is a debilitating condition affecting millions, particularly older adults, leading to reduced quality of life and increased mortality. Many individuals with CHF, especially those over 50 years old, also exhibit lower than normal levels of growth hormone (GH) effect, often associated with aging. This study aimed to investigate whether restoring growth hormone levels through Growth Hormone Releasing Hormone (GHRH) therapy could strengthen heart muscles and improve cardiac function in these patients.
Results
The study revealed significant improvements in cardiac function and patient-reported outcomes in the GHRH treatment group. Patients receiving tesamorelin demonstrated a statistically significant increase in Left Ventricular Ejection Fraction (LVEF) by an average of 5.2% from baseline, compared to a modest 1.1% increase in the placebo group (p<0.01). Furthermore, the GHRH group experienced a 10.3% reduction in Left Ventricular End-Diastolic Diameter (LVEDD), indicating improved cardiac remodeling, whereas the placebo group showed only a 2.1% reduction (p<0.05). GHRH therapy significantly improved cardiac function, increasing Left Ventricular Ejection Fraction by an average of 5.2% compared to placebo, suggesting a direct benefit on heart pumping efficiency. Quality of life, assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ), showed an average 15.8-point improvement in the tesamorelin group versus a 3.5-point improvement in the placebo group (p<0.001). Serum IGF-1 levels, a marker of GH activity, increased 2.7-fold in the GHRH group, confirming the intended biological effect (p<0.001).
Why It Matters
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect. The observed improvements in LVEF and cardiac remodeling are clinically meaningful, potentially slowing disease progression. If validated in larger, longer-term studies, GHRH analogs like tesamorelin could be repurposed for clinical use in this vulnerable patient population. Future research should focus on Phase II and III human trials to confirm these benefits, assess long-term safety, and determine optimal dosing regimens.